Integration of hepatic drug transporters and phase II metabolizing enzymes: Mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites

被引:188
作者
Zamek-Gliszczynski, MJ [1 ]
Hoffmaster, KA [1 ]
Nezasa, K [1 ]
Tallman, MN [1 ]
Brouwer, KLR [1 ]
机构
[1] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA
关键词
phase II metabolism; transport; sulfation; glucuronidation; glutathione conjugation; multidrug resistance-associated protein; breast cancer resistance protein; liver;
D O I
10.1016/j.ejps.2005.12.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The liver is the primary site of drug metabolism in the body Typically, metabolic conversion of a drug results in inactivation, detoxification, and enhanced likelihood for excretion in urine or feces. Sulfation, glucuronidation, and glutathione conjugation represent the three most prevalent classes of phase 11 metabolism, which may occur directly on the parent compounds that contain appropriate structural motifs, or, as is usually the case, on functional groups added or exposed by phase I oxidation. These three conjugation reactions increase the molecular weight and water solubility of the compound, in addition to adding a negative charge to the molecule. As a result of these changes in the physicochemical properties, phase II conjugates tend to have very poor membrane permeability, and necessitate carrier-mediated transport for biliary or hepatic basolateral excretion into sinusoidal blood for eventual excretion into urine. This review summarizes sulfation, glucuronidation, and glutathione conjugation reactions, as well as recent progress in elucidating the hepatic transport mechanisms responsible for the excretion of these conjugates from the liver. The discussion focuses on alterations of metabolism and transport by chemical modulators, and disease states, as well as pharmacodynamic and toxicological implications of hepatic metabolism and/or transport modulation for certain active phase II conjugates. A brief discussion of issues that must be considered in the design and interpretation of phase II metabolite transport studies follows. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:447 / 486
页数:40
相关论文
共 329 条
[1]  
ABERNETHY DR, 1985, J PHARMACOL EXP THER, V234, P345
[2]   Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen [J].
Adachi, Y ;
Suzuki, H ;
Schinkel, AH ;
Sugiyama, Y .
MOLECULAR PHARMACOLOGY, 2005, 67 (03) :923-928
[3]   FUNCTIONAL INTEGRITY OF HEPATOCYTE CANALICULAR MEMBRANE-TRANSPORT OF TAUROCHOLATE AND BILIRUBIN DIGLUCURONIDE IN EISAI HYPERBILIRUBINURIA RATS [J].
ADACHI, Y ;
KOBAYASHI, H ;
SHOUJI, M ;
KITANO, M ;
OKUYAMA, Y ;
YAMAMOTO, T .
LIFE SCIENCES, 1993, 52 (09) :777-784
[4]   Transport activity of human MRP3 expressed in Sf9 cells: Comparative studies with rat MRP3 [J].
Akita, H ;
Suzuki, H ;
Hirohashi, T ;
Takikawa, H ;
Sugiyama, Y .
PHARMACEUTICAL RESEARCH, 2002, 19 (01) :34-41
[5]   Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump [J].
Akita, H ;
Suzuki, H ;
Ito, K ;
Kinoshita, S ;
Sato, N ;
Takikawa, H ;
Sugiyama, Y .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2001, 1511 (01) :7-16
[6]   Garlic attenuates chrysotile-mediated pulmonary toxicity in rats by altering the phase I and phase II drug metabolizing enzyme system [J].
Ameen, M ;
Musthapa, MS ;
Abidi, P ;
Ahmad, I ;
Rahman, Q .
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2003, 17 (06) :366-371
[7]  
ASSEM M, 2004, J BIOL CHEM
[8]   Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione [J].
Bai, J ;
Lai, LQ ;
Yeo, HC ;
Goh, BC ;
Tan, TMC .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (02) :247-257
[9]   Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions [J].
Bakos, É ;
Evers, R ;
Sinkó, E ;
Váradi, A ;
Borst, P ;
Sarkadi, B .
MOLECULAR PHARMACOLOGY, 2000, 57 (04) :760-768
[10]  
BALLATORI N, 1995, HEPATOLOGY, V22, P1469, DOI 10.1016/0270-9139(95)90154-X